Primary outcomeLeast squares mean· Week 0, week 40
Change in HbA1c
| Group | Value (percentage of HbA1c) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -1.51 | 0.06 |
| Semaglutide 1.0 mg | -1.78 | 0.06 |
| Dulaglutide 0.75 mg | -1.11 | 0.05 |
| Dulaglutide 1.5 mg | -1.37 | 0.06 |
Trial · Interventional
CompletedPhase 3Results postedRegistry dataEfficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
Short name SUSTAIN 7
NCTNCT02648204 (opens ClinicalTrials.gov in a new tab)Other idNN9535-4216Other id2014-005375-91Other idU1111-1164-8495Other id2014
Overview
- Status
- Completed
- Phase
- Phase 3
- Enrollment
- 1,201 participants (actual)
- Sponsor
- Novo Nordisk A/S · Industry
- Design
- Randomized · Open label (no masking)
- Countries
17 countries
United States, Bulgaria, Croatia, Finland, Germany, Greece, Hong Kong, India, Ireland, Latvia, Lithuania, Portugal, Puerto Rico, Romania, Slovakia, Spain, United Kingdom
- Start
- 6 Jan 2016
- Primary completion
- 10 Apr 2017
- Completion
- 19 May 2017
- First posted
- 6 Jan 2016 (estimated)
- Last update posted
- 15 Oct 2019
- Conditions
- Diabetes · Diabetes Mellitus, Type 2
Timeline
1 trial · 1 completed · 1 with posted results
- Completed
- Ongoing
- Not yet recruiting
- Stopped
- Estimated dates (est.)
- Results posted
201620172018
- Ph 3
Registry summary
Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
Interventions
- semaglutideDrug
- DulaglutideDrug
Arms4
Experimental
Semaglutide 0.5 mg/Week
Experimental
Semaglutide 1.0 mg/Week
Active comparator
Dulaglutide 0.75 mg/Week
Active comparator
Dulaglutide 1.5 mg/Week
Primary outcomes1
Outcomes the sponsor listed as primary.
Change in HbA1c
Time frame · Week 0, week 40
Registry description
Results are based on HbA1c data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on-treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Secondary outcomes(20)
Change in Body Weight (kg)
Time frame · Week 0, week 40
Registry description
Results are based on body weight data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.
Change in Fasting Plasma Glucose
Time frame · Week 0, week 40
Registry description
Results are based on fasting plasma glucose data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.
Change in Systolic and Diastolic Blood Pressure
Time frame · Week 0, week 40
Registry description
Results are based on systolic and diastolic blood pressure data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication.
Change in Overall Scores for Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire
Time frame · Week 0, week 40
Registry description
The questionnaire contains 8 items and evaluates subjects' diabetes treatment in terms of convenience, flexibility and general feelings towards treatment. The result presented is 'Treatment Satisfaction' summary score (sum of 6 of the 8 items). Response options: 6 (best case) to 0 (worst case). Total scores range: 0-36. Higher scores=higher satisfaction. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This includes observations recorded at, or after the date of first dose of trial product and not after first occurrence of following: the end-date of the 'on-treatment' observation period or initiation of rescue medication
HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target
Time frame · After 40 weeks treatment
Registry description
Percentage of subjects who achieved HbA1c target below or equal to 6.5% (48 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Change From Baseline in 7-point Self-measured Plasma Glucose (SMPG) Mean Profile
Time frame · Week 0, week 40
Registry description
SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are mean profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Change From Baseline 7-point Self-measured Plasma Glucose Increment
Time frame · Week 0, week 40
Registry description
SMPG values were recorded at 7 time-points: before and 90 minutes after start of breakfast, lunch, and dinner, and at bedtime. Reported results are plasma glucose incremental profile from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit
Change in Fasting Blood Lipids (Total Cholesterol)
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.
Change in Fasting Blood Lipids (Low Density Lipoprotein [LDL] Cholesterol)
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.
Change in Fasting Blood Lipids (High Density Lipoprotein [HDL] Cholesterol)
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.
Change in Fasting Blood Lipids (Triglycerides)
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit. Change from baseline is presented in terms of ratio to baseline value.
Change in Body Mass Index (BMI)
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Change in Waist Circumference
Time frame · Week 0, week 40
Registry description
Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Change in Short Form Health Survey (SF-36v2™)
Time frame · Week 0, week 40
Registry description
The questionnaire contains 36 items across 8 domains and 2 summary scores. Score range: 0 (worst score) to 100 (best score). Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. The post-baseline responses are analysed using a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) American Diabetes Association (ADA) Target
Time frame · After 40 weeks of treatment
Registry description
Percentage of subjects who achieved HbA1c target below or equal to \<7.0% (53 mmol/mol) after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥5%
Time frame · After 40 weeks treatment
Registry description
Percentage of subjects who achieved weight loss ≥5% after 40 weeks of treatment. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥10%
Time frame · After 40 weeks treatment
Registry description
Percentage of subjects who achieved weight loss ≥10% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c <7.0% (53 mmol/Mol) Without Severe or Blood Glucose (BG) Confirmed Symptomatic Hypoglycaemia Episodes and no Weight Gain
Time frame · After 40 weeks of treatment
Registry description
Percentage of subjects achieved (yes/no) HbA1c \<7.0% (53 mmol/mol) without severe or BG confirmed symptomatic hypoglycaemia episodes and no weight gain after 40 weeks of treatment. Results are based on data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was period where subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was subset of 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) HbA1c Reduction ≥1%
Time frame · After 40 weeks of treatment
Registry description
Percentage of subjects who achieved (yes/no) HbA1c reduction of ≥1% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Subjects Who After 40 Weeks Treatment Achieve (Yes/no) Weight Loss ≥3%
Time frame · After 40 weeks treatment
Registry description
Percentage of subjects who achieved (yes/no) weight loss of ≥3% after 40 weeks of treatment. Results are based on the data from on-treatment without rescue medication observation period. The 'on-treatment' observation period was the period where the subject was considered to be exposed to trial product. The 'on-treatment without rescue medication' observation period was a subset of the 'on -treatment' observation period, where subjects did not receive any non-investigational antidiabetic medication (rescue medication). This period includes the observations recorded at, or after the date of first dose of trial product and not after the first occurrence of the following: the end-date of the 'on-treatment' observation period or initiation of rescue medication. Missing data imputed from a mixed model for repeated measurements with treatment and country as fixed factors and baseline value as covariate, all nested within visit.
Posted results
Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.
Primary outcome results
Secondary and other outcome results(7)
Secondary outcomeLeast squares mean· Week 0, week 40
Change in Body Weight (kg)
| Group | Value (kg) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -4.56 | 0.28 |
| Semaglutide 1.0 mg | -6.53 | 0.28 |
| Dulaglutide 0.75 mg | -2.30 | 0.27 |
| Dulaglutide 1.5 mg | -2.98 | 0.27 |
Secondary outcomeLeast squares mean· Week 0, week 40
Change in Fasting Plasma Glucose
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -2.18 | 0.12 |
| Semaglutide 1.0 mg | -2.83 | 0.12 |
| Dulaglutide 0.75 mg | -1.87 | 0.12 |
| Dulaglutide 1.5 mg | -2.25 | 0.12 |
Secondary outcomeLeast squares mean· Week 0, week 40
Change in Systolic and Diastolic Blood Pressure
| Group | Value (mmHg) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -0.57 | 0.48 |
| Semaglutide 1.0 mg | -2.05 | 0.49 |
| Dulaglutide 0.75 mg | -0.35 | 0.47 |
| Dulaglutide 1.5 mg | -0.03 | 0.47 |
Secondary outcomeLeast squares mean· Week 0, week 40
Change in Overall Scores for Patient Reported Outcomes: Diabetes Treatment Satisfaction Questionnaire
| Group | Value (units on a scale) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | 4.60 | 0.28 |
| Semaglutide 1.0 mg | 4.55 | 0.29 |
| Dulaglutide 0.75 mg | 4.52 | 0.28 |
| Dulaglutide 1.5 mg | 4.65 | 0.28 |
Secondary outcomeNumber· After 40 weeks treatment
HbA1c Below or Equal to 6.5% (48 mmol/Mol) American Association of Clinical Endocrinologists Target
| Group | Value (percentage of subjects) |
|---|---|
| Semaglutide 0.5 mg | 49.2 |
| Semaglutide 1.0 mg | 66.7 |
| Dulaglutide 0.75 mg | 34.1 |
| Dulaglutide 1.5 mg | 47.2 |
Secondary outcomeLeast squares mean· Week 0, week 40
Change From Baseline in 7-point Self-measured Plasma Glucose (SMPG) Mean Profile
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -2.43 | 0.10 |
| Semaglutide 1.0 mg | -2.95 | 0.10 |
| Dulaglutide 0.75 mg | -1.99 | 0.10 |
| Dulaglutide 1.5 mg | -2.32 | 0.10 |
Secondary outcomeLeast squares mean· Week 0, week 40
Change From Baseline 7-point Self-measured Plasma Glucose Increment
| Group | Value (mmol/L) | Spread |
|---|---|---|
| Semaglutide 0.5 mg | -0.77 | 0.08 |
| Semaglutide 1.0 mg | -0.93 | 0.09 |
| Dulaglutide 0.75 mg | -0.44 | 0.08 |
| Dulaglutide 1.5 mg | -0.63 | 0.08 |
Adverse events, as posted
| Group | Deaths | Serious events | Other events |
|---|---|---|---|
| Semaglutide 0.5 mgSubjects received s.c. injections of semaglutide OW for treatment duration of 40 weeks. Subjects received semaglutide 0.25 mg for 4 weeks (weeks 1 to 4) followed by 0.5 mg for 36 weeks (weeks 5 to 40). | 0 / 301 | 17 / 301 | 132 / 301 |
| Semaglutide 1.0 mgSubjects received s.c. injections of semaglutide OW for treatment duration of 40 weeks. Subjects received semaglutide 0.25 mg for 4 weeks (weeks 1 to 4) followed by 0.5 mg for another 4 weeks (weeks 5 to 8) and then semaglutide 1.0 mg for remaining 32 weeks (weeks 9-40). Subjects were followed for 5 weeks after completion of treatment period. | 1 / 300 | 23 / 300 | 134 / 300 |
| Dulaglutide 0.75 mgSubjects received s.c. injections of dulaglutide 0.75 mg OW for treatment duration of 40 weeks. Subjects were followed for 5 weeks after completion of treatment period. | 2 / 299 | 24 / 299 | 106 / 299 |
| Dulaglutide 1.5 mgSubjects received s.c. injections of dulaglutide 1.5 mg OW for treatment duration of 40 weeks. Subjects were followed for 5 weeks after completion of treatment period. | 2 / 299 | 22 / 299 | 139 / 299 |
Each cell reads participants affected / participants at risk, as the registry posted them.
Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works
Studies13
Studies that cite this trial.
Studies with results
12 studies on this page
Indexing hint: Randomized controlled trial · 2024
9 results
Tirzepatide 5, 10 and 15 mg versus injectable semaglutide 0.5 mg for the treatment of type 2 diabetes: An adjusted indirect treatment comparison.
Osumili et al. 2024Diabetes research and clinical practicecited by 2
PMID 38777128DOI 10.1016/j.diabres.2024.111717PUB-38777128
Full text at the publisher9 results
Indexing hint: Randomized controlled trial · 2020
9 results
Efficacy and Safety of Semaglutide for Type 2 Diabetes by Race and Ethnicity: A Post Hoc Analysis of the SUSTAIN Trials.
DeSouza et al. 2020The Journal of clinical endocrinology and metabolismcited by 43
PMID 31769496DOI 10.1210/clinem/dgz072PUB-31769496
Rights unknown9 results
PubMed tag: none · 2020
11 results
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses.
Pratley et al. 2020BMJ opencited by 18
PMID 33199417PMC7670946DOI 10.1136/bmjopen-2020-037883PUB-33199417
Free to read · publisher termsCC BY-NC11 results
PubMed tag: none · 2019
5 results
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
Viljoen et al. 2019Diabetes, obesity & metabolismcited by 41
PMID 30362224PMC6587509DOI 10.1111/dom.13564PUB-30362224
Free to read · publisher termsCC BY-NC-ND5 results
PubMed tag: none · 2019
8 results
GREATER COMBINED REDUCTIONS IN HbA1C ≥1.0% AND WEIGHT ≥5.0% WITH SEMAGLUTIDE VERSUS COMPARATORS IN TYPE 2 DIABETES.
Rodbard et al. 2019Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistscited by 17
PMID 30865526DOI 10.4158/ep-2018-0444PUB-30865526
Full text at the publisher8 results
PubMed tag: none · 2019
6 results
Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Johansen et al. 2019PharmacoEconomics - opencited by 27
PMID 30927241PMC6861407DOI 10.1007/s41669-019-0131-6PUB-30927241
Free to read · publisher termsCC BY-NC6 results
Indexing hint: Observational study · 2019
10 results
The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin et al. 2019Advances in therapycited by 11
PMID 31168765PMC6822857DOI 10.1007/s12325-019-00965-yPUB-31168765
Free to read · publisher termsCC BY-NC10 results
Indexing hint: Randomized controlled trial · 2019
6 results
Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
Jendle et al. 2019Diabetes, obesity & metabolismcited by 17
PMID 31215727PMC6771774DOI 10.1111/dom.13816PUB-31215727
Free to read · publisher termsCC BY-NC6 results
Indexing hint: Randomized controlled trial · 2018
11 results
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Ahmann et al. 2018Diabetes carecited by 481
PMID 29246950DOI 10.2337/dc17-0417PUB-29246950
Full text at the publisher11 results
Indexing hint: Randomized controlled trial · 2018
21 results
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley et al. 2018The lancet. Diabetes & endocrinologycited by 614
PMID 29397376DOI 10.1016/s2213-8587(18)30024-xPUB-29397376
Full text at the publisher21 results
PubMed tag: none · 2018
10 results
Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States.
Wilkinson et al. 2018Diabetes therapy : research, treatment and education of diabetes and related disorderscited by 18
PMID 29557057PMC5984908DOI 10.1007/s13300-018-0402-8PUB-29557057
Free to read · publisher termsCC BY-NC10 results
Indexing hint: Systematic review · 2018
5 results
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Sharma et al. 2018Current medical research and opinioncited by 24
PMID 29764222DOI 10.1080/03007995.2018.1476332PUB-29764222
Full text at the publisher5 results
More studies
1 study on this page
Indexing hint: Review · 2019
Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials.
Aroda et al. 2019Diabetes & metabolismcited by 227
PMID 30615985DOI 10.1016/j.diabet.2018.12.001PUB-30615985
Full text at the publisher
Eligibility
Who could join, as posted.
- Sex
- All
- Age
- from 18 Years
- Healthy volunteers
- Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed consent. - HbA1c (glycosylated haemoglobin) 7.0 - 10.5% (53 - 91 mmol/mol) (both inclusive) - Subjects on stable diabetes treatment with metformin (minimum of 1500 mg/day or maximal tolerated dose documented in the patient medical record) for 90 days prior to screening Exclusion Criteria: - Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using an adequate contraceptive method (adequate contraceptive measures as required by local regulation or practice) - Any condition, which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol - Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 days before screening. An exception is short-term insulin treatment for acute illness for a total of equal to or below 14 days - History of pancreatitis (acute or chronic) - Screening calcitonin equal to or above 50 ng/L - Family or personal history of Multiple Endocrine Neoplasia Type 2 or Medullary Thyroid Carcinoma - Renal impairment defined as eGFR (electronic case report form) below 60 mL/min/1.73 m\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) - Subjects presently classified as being in New York Heart Association Class IV - Planned coronary, carotid or peripheral artery revascularisation on the day of screening - Proliferative retinopathy or maculopathy requiring acute treatment - History or presence of malignant neoplasms within the last 5 years (except basal and squamous cell skin cancer and in-situ carcinomas) - Anticipated initiation or change in concomitant medications (for more than 14 consecutive days or on a frequent basis) known to affect weight or glucose metabolism (e.g. orlistat, thyroid hormones, corticosteroids)
PepBank is a research reference. Talk to a doctor before you use any peptide.